Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ERN1 | O75460 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2329831 | 0.88 | ALDH1A1 (0.44) | ALDH1A1GAAKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL5561336 | 0.86 | PPARA (0.48) | POLBGAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1332621 | 0.86 | PPARA (0.48) | POLBGAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL2560273 | 0.85 | MEN1 (0.43) | ALDH1A1POLBGAAKDM4ERAB9A | |
| SCHEMBL21381326 | 0.83 | SMN1; SMN2 (0.57) | ALDH1A1POLBGAAKDM4ESMN1; SMN2 | |
| SCHEMBL28257746 | 0.82 | TSHR (0.55) | ALDH1A1POLBGAAKDM4ERAB9A | |
| SCHEMBL1332620 | 0.82 | TSHR (0.48) | ALDH1A1GAAKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL692616 | 0.80 | PTGDR2 (0.41) | ALDH1A1GAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL2330339 | 0.77 | PPARA (0.44) | ALDH1A1MAPTTDP1L3MBTL1TSHR | |
| SCHEMBL29956946 | 0.76 | SMN1; SMN2 (0.52) | ALDH1A1GAAKDM4ESMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421866-A1 | 3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| US-8076482-B2 | 3,3′-spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076482-B2 | 3,3′-spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076482-B2 | 3,3′-spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| EP-2389381-A1 | SPIROINDOLINONE DERIVATIVE PRODRUGS | F. Hoffmann-La Roche AG (CH) | 2011-11-30 | — | — | EP | disclosed |
| US-8038247-B2 | Recording apparatus and recording method | CANON KABUSHIKI KAISHA (JP) | 2011-10-18 | — | — | US | disclosed |
| EP-2235017-B1 | SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2011-09-14 | — | — | EP | disclosed |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | CHEN LI | 2010-10-28 | — | — | US | disclosed |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | CHEN LI | 2010-10-28 | — | — | US | disclosed |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | CHEN LI | 2010-10-28 | — | — | US | disclosed |
| US-7776875-B2 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | HOFFMAN-LA ROCHE INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776875-B2 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | HOFFMAN-LA ROCHE INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100190814-A1 | SPIROINDOLINONE DERIVATIVE PRODRUGS | CHEN LI | 2010-07-29 | — | — | US | disclosed |
| US-20100190814-A1 | SPIROINDOLINONE DERIVATIVE PRODRUGS | CHEN LI | 2010-07-29 | — | — | US | disclosed |
| US-20100190814-A1 | SPIROINDOLINONE DERIVATIVE PRODRUGS | CHEN LI | 2010-07-29 | — | — | US | disclosed |
| WO-2010084097-A1 | SPIROINDOLINONE DERIVATIVE PRODRUGS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-29 | — | — | WO | disclosed |
| WO-2009080488-A1 | SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163512-A1 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | CHEN LI | 2009-06-25 | — | — | US | disclosed |
| US-20090163512-A1 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | CHEN LI | 2009-06-25 | — | — | US | disclosed |
| US-20090163512-A1 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | CHEN LI | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190814-A1 | SPIROINDOLINONE DERIVATIVE PRODRUGS | CCNE1, CCNE2, CCND1 | ALDH1A1 118/4885POLB 3064/4885GAA 2271/4885 |
| US-20090163512-A1 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | TOP2B, TOP2A, CCNY | ALDH1A1 463/4885POLB 207/4885GAA 2970/4885 |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | SIK3, RB1, CCND3 | ALDH1A1 1228/4885POLB 2539/4885GAA 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.